%0 Journal Article %T MicroRNA-143 is Associated With Pathological Complete Response and Regulates Multiple Signaling Proteins in Breast Cancer %A Abelardo Meneses-Garc¨ªa %A Carlos P¨¦rez-Plasencia %A Claudia Arce-Salinas %A C¨¦sar L¨®pez-Camarillo %A Enrique Bargallo-Rocha %A Erika Ru¨ªz-Garc¨ªa %A Horacio Astudillo-de la Vega %A Jos¨¦ Sullivan L¨®pez-Gonz¨¢lez %A Laurence A. Marchat %A Maribel Aguilar-Medina %A Ra¨²l Garc¨ªa-V¨¢zquez %A Rosal¨ªo Ramos-Pay¨¢n %A ¨¢ngeles Carlos-Reyes %J Archive of "Technology in Cancer Research & Treatment". %D 2019 %R 10.1177/1533033819827309 %X Almost 55% to 80% of patients with breast cancer have an unfavorable pathological complete response to chemotherapy. MicroRNAs are small noncoding RNAs involved in cancer progression; however, their utility as predictors of pathological complete response to neoadjuvant chemotherapy is unclear. Here, we investigated if miR-143 could discriminate between pathological complete response and no-polymerase chain reaction of patients with locally advanced triple negative breast cancer that have received a fluorouracil-cisplatin/paclitaxel-based neoadjuvant treatment. Data showed that miR-143 exhibited a significant low expression (P < .0006) in patients that achieved pathological complete response in comparison to nonresponder group. Receiver operating characteristic curve analysis suggested that miR-143 could be a good predictor of pathological complete response (area under curve = 0.849, P < .0006). Moreover, Kaplan-Meier analysis indicated that before neoadjuvant therapy low levels of miR-143 were associated to increased disease free survival. To gain insights into cellular functions of miR-143, we firstly showed that miR-143 was severely repressed in breast cancer cell lines and tumors in comparison to normal mammary cells and tissues. Ectopic restoration of miR-143 using RNA mimics inhibited both cell proliferation and migration and sensitized breast cancer cells to cisplatin therapy in vitro. To decipher the signaling networks regulated by miR-143, we used a high-throughput enzyme-linked immunosorbent assay-based phosphorylation antibody array. Phospho-proteomic profiling revealed that miR-143 coordinately reduced the protein levels and phosphorylation status of multiple oncoproteins involved in AKT, WNT/¦Â-catenin, SAPK/JNK, FAK, and JAK/STAT signaling pathways. Moreover, low miR-143 and high GSK3-¦Â, RAF1, paxillin, and p21CIP1 expression levels in a large cohort of patients with breast cancer were associated with worst outcome. In summary, miR-143 could be a potential predictor of response to neoadjuvant therapy and it may function as a divergent regulator of diverse signaling networks to suppress cell proliferation and migration in breast cancer %K breast cancer %K pathological complete response %K neoadjuvant therapy %K miR-143 %K cell proliferation %K cell migration %K signaling pathways %U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378643/